Difference between revisions of "Part:BBa K3740042"

 
Line 2: Line 2:
 
__NOTOC__
 
__NOTOC__
 
<partinfo>BBa_K3740042 short</partinfo>
 
<partinfo>BBa_K3740042 short</partinfo>
 +
===Description===
 +
We replaced the nuclease domain of pyocin S2 with that of colicin E3 to produce a chimeric bacteriocin termed SE.
  
−
chimeric bacteriocin
+
===Sequence and Features===
−
 
+
−
<!-- Add more about the biology of this part here
+
−
===Usage and Biology===
+
−
 
+
−
<!-- -->
+
−
<span class='h3bb'>Sequence and Features</span>
+
 
<partinfo>BBa_K3740042 SequenceAndFeatures</partinfo>
 
<partinfo>BBa_K3740042 SequenceAndFeatures</partinfo>
  
Line 17: Line 13:
 
<partinfo>BBa_K3740042 parameters</partinfo>
 
<partinfo>BBa_K3740042 parameters</partinfo>
 
<!-- -->
 
<!-- -->
 +
 +
=2021 SZPT-China=
 +
<h3>Biology</h3>
 +
The receptor domain, translocase domain of pyocin S2 and the nuclease domain of colicin E3 are fused together to get a new chimeric bacteriocin termed SE. The antipseudomonal SE protein can target and inhibit P. aeruginosa, even including those harbouring a S2 immunity protein IMMs2

Revision as of 06:48, 19 October 2021


Chimeric Bacteriocin SE

Description

We replaced the nuclease domain of pyocin S2 with that of colicin E3 to produce a chimeric bacteriocin termed SE.

Sequence and Features


Assembly Compatibility:
  • 10
    INCOMPATIBLE WITH RFC[10]
    Illegal EcoRI site found at 2407
  • 12
    INCOMPATIBLE WITH RFC[12]
    Illegal EcoRI site found at 2407
  • 21
    INCOMPATIBLE WITH RFC[21]
    Illegal EcoRI site found at 2407
    Illegal BglII site found at 2112
    Illegal BamHI site found at 1684
  • 23
    INCOMPATIBLE WITH RFC[23]
    Illegal EcoRI site found at 2407
  • 25
    INCOMPATIBLE WITH RFC[25]
    Illegal EcoRI site found at 2407
    Illegal NgoMIV site found at 1483
    Illegal AgeI site found at 1573
  • 1000
    COMPATIBLE WITH RFC[1000]


2021 SZPT-China

Biology

The receptor domain, translocase domain of pyocin S2 and the nuclease domain of colicin E3 are fused together to get a new chimeric bacteriocin termed SE. The antipseudomonal SE protein can target and inhibit P. aeruginosa, even including those harbouring a S2 immunity protein IMMs2